Clinical trials focusing on EGFR/ALK/KRAS, MET/HGF, and RANK/RANKL signaling have highlighted potential therapies for advanced NSCLC with or without distant metastasis. This evidence concerns the gene KRAS and non-small cell lung carcinoma.